{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T04:58:03Z","timestamp":1789880283180,"version":"4.0.1"},"reference-count":38,"publisher":"SAGE Publications","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAD"],"published-print":{"date-parts":[[2018,8,7]]},"DOI":"10.3233\/jad-180145","type":"journal-article","created":{"date-parts":[[2018,7,17]],"date-time":"2018-07-17T12:19:54Z","timestamp":1531829994000},"page":"3-13","source":"Crossref","is-referenced-by-count":51,"title":["Alzheimer\u2019s Disease: Advances in Drug Development"],"prefix":"10.1177","volume":"65","author":[{"given":"Morgane","family":"Piton","sequence":"first","affiliation":[{"name":"University of Montpellier, Montpellier, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Hirtz","sequence":"additional","affiliation":[{"name":"Clinical Proteomics Platform, LBPC, IRMB, CHU Montpellier, Montpellier University, Montpellier, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Desmetz","sequence":"additional","affiliation":[{"name":"BioCommunication en CardioM\u00e9tabolique (BC M), University of Montpellier, Montpellier France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacqueline","family":"Milhau","sequence":"additional","affiliation":[{"name":"BioCommunication en CardioM\u00e9tabolique (BC M), University of Montpellier, Montpellier France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne Dominique","family":"Lajoix","sequence":"additional","affiliation":[{"name":"BioCommunication en CardioM\u00e9tabolique (BC M), University of Montpellier, Montpellier France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karim","family":"Bennys","sequence":"additional","affiliation":[{"name":"Department of Neurology, Memory Research and Resources Center, Montpellier University Hospital, University of Montpellier, Montpellier, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvain","family":"Lehmann","sequence":"additional","affiliation":[{"name":"Clinical Proteomics Platform, LBPC, IRMB, CHU Montpellier, Montpellier University, Montpellier, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Audrey","family":"Gabelle","sequence":"additional","affiliation":[{"name":"University of Montpellier, Montpellier, France"},{"name":"Department of Neurology, Memory Research and Resources Center, Montpellier University Hospital, University of Montpellier, Montpellier, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","reference":[{"key":"10.3233\/JAD-180145_ref1","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S1474-4422(13)70276-X","article-title":"Targeting the \u03b2 secretase BACE1 for Alzheimer\u2019s disease therapy","volume":"13","author":"Yan","year":"2014","journal-title":"Lancet Neurol"},{"key":"10.3233\/JAD-180145_ref2","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/s13195-014-0089-7","article-title":"BACE1 inhibitor drugs in clinical trials for Alzheimer\u2019s disease","volume":"6","author":"Vassar","year":"2014","journal-title":"Alzheimers Res Ther"},{"key":"10.3233\/JAD-180145_ref3","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1002\/jcph.950","article-title":"BACE1 inhibitor Lanabecestat (AZD3293) in a phase 1 study of healthy Japanese subjects: Pharmacokinetics and effects on plasma and cerebrospinal fluid a\u03b2 peptides","volume":"57","author":"Sakamoto","year":"2017","journal-title":"J Clin Pharmacol"},{"key":"10.3233\/JAD-180145_ref6","unstructured":"Alzheimer Research Forum, Drugs in Clinical Trials: Lanabecestat. https:\/\/www.alzforum.org\/therapeutics\/azd3293, Accessed on January 3, 2018."},{"key":"10.3233\/JAD-180145_ref8","unstructured":"Janssen Research & Development LLC (2015) An efficacy and safety study of Atabecestat in participants who are asymptomatic at risk for developing Alzheimer\u2019s dementia (EARLY) - ClinicalTrials.gov. Last updated March 9, 2018, Accessed on March 29, 2018."},{"key":"10.3233\/JAD-180145_ref11","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1038\/nn1531","article-title":"Targeting BACE1 with siRNAs ameliorates Alzheimer disease neuropathology in a transgenic model","volume":"8","author":"Singer","year":"2005","journal-title":"Nat Neurosci"},{"key":"10.3233\/JAD-180145_ref12","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/s13024-015-0033-8","article-title":"A novel BACE inhibitor NB-360 shows a superior pharmacological profile and robust reduction of amyloid-\u03b2 and neuroinflammation in APP transgenic mice","volume":"10","author":"Neumann","year":"2015","journal-title":"Mol Neurodegener"},{"key":"10.3233\/JAD-180145_ref17","doi-asserted-by":"crossref","first-page":"S411","DOI":"10.1016\/j.jalz.2013.11.004","article-title":"Lessons from a BACE1 inhibitor trial: Off-site but not off base","volume":"10","author":"Lahiri","year":"2014","journal-title":"Alzheimers Dement"},{"key":"10.3233\/JAD-180145_ref18","doi-asserted-by":"crossref","first-page":"2898","DOI":"10.1016\/j.bbamem.2013.06.005","article-title":"\u03b3-Secretase inhibitors and modulators","volume":"1828","author":"Golde","year":"2013","journal-title":"Biochim Biophys Acta"},{"key":"10.3233\/JAD-180145_ref19","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1056\/NEJMoa1210951","article-title":"A phase 3 trial of Semagacestat for treatment of Alzheimer\u2019s disease","volume":"369","author":"Doody","year":"2013","journal-title":"N Engl J Med"},{"key":"10.3233\/JAD-180145_ref20","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/1471-2202-14-44","article-title":"Multi-target action of the novel anti-Alzheimer compound CHF5074: In vivo study of long term treatment in Tg2576 mice","volume":"14","author":"Sivilia","year":"2013","journal-title":"BMC Neurosci"},{"key":"10.3233\/JAD-180145_ref22","doi-asserted-by":"crossref","first-page":"22","DOI":"10.2174\/1567205012666141218141904","article-title":"Acute oral Bryostatin-1 administration improves learning deficits in the APP\/PS1 transgenic mouse model of Alzheimer\u2019s disease","volume":"12","author":"Schrott","year":"2015","journal-title":"Curr Alzheimer Res"},{"key":"10.3233\/JAD-180145_ref24","doi-asserted-by":"crossref","first-page":"56","DOI":"10.3389\/fnmol.2017.00056","article-title":"Regulation of alpha-secretase ADAM10 in vitro and in vivo: Genetic, epigenetic, and protein-based mechanisms","volume":"10","author":"Endres","year":"2017","journal-title":"Front Mol Neurosci"},{"key":"10.3233\/JAD-180145_ref25","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1007\/s00401-015-1498-9","article-title":"Viral gene transfer of APPs\u03b1 rescues synaptic failure in an Alzheimer\u2019s disease mouse model","volume":"131","author":"Fol","year":"2016","journal-title":"Acta Neuropathol"},{"key":"10.3233\/JAD-180145_ref26","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1007\/s40263-016-0364-1","article-title":"A\u03b2-degrading proteases: Therapeutic potential in Alzheimer disease","volume":"30","author":"Leissring","year":"2016","journal-title":"CNS Drugs"},{"key":"10.3233\/JAD-180145_ref27","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1038\/mt.2008.148","article-title":"Adeno-associated viral (AAV) serotype 5 vector mediated gene delivery of endothelin-converting enzyme reduces A\u03b2 deposits in APP + PS1 transgenic mice","volume":"16","author":"Carty","year":"2008","journal-title":"Mol Ther"},{"key":"10.3233\/JAD-180145_ref28","doi-asserted-by":"crossref","first-page":"e59626","DOI":"10.1371\/journal.pone.0059626","article-title":"Intracranial injection of AAV expressing NEP but not IDE reduces amyloid pathology in APP+PS1 transgenic mice","volume":"8","author":"Carty","year":"2013","journal-title":"PloS One"},{"key":"10.3233\/JAD-180145_ref29","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/scrt440","article-title":"Neural stem cells genetically-modified to express neprilysin reduce pathology in Alzheimer transgenic models","volume":"5","author":"Blurton-Jones","year":"2014","journal-title":"Stem Cell Res Ther"},{"key":"10.3233\/JAD-180145_ref30","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1111\/joim.12168","article-title":"Amyloid-\u00df-directed immunotherapy for Alzheimer\u2019s disease","volume":"275","author":"Lannfelt","year":"2014","journal-title":"J Intern Med"},{"key":"10.3233\/JAD-180145_ref31","doi-asserted-by":"crossref","first-page":"4923","DOI":"10.1523\/JNEUROSCI.4672-12.2013","article-title":"Immunogenicity, efficacy, safety, and mechanism of action of epitope vaccine (Lu AF20513) for Alzheimer\u2019s disease: Prelude to a clinical trial","volume":"33","author":"Davtyan","year":"2013","journal-title":"J Neurosci"},{"key":"10.3233\/JAD-180145_ref32","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1586\/1744666X.2014.883921","article-title":"Amyloid-based immunotherapy for Alzheimer\u2019s disease in the time of prevention trials: The way forward","volume":"10","author":"Panza","year":"2014","journal-title":"Expert Rev Clin Immunol"},{"key":"10.3233\/JAD-180145_ref33","unstructured":"Novartis Pharmaceuticals (2015) A study of CAD106 and CNP520 versus placebo in participants at risk for the onset of clinical symptoms of Alzheimer\u2019s disease - ClinicalTrials.gov. Last updated December 5, 2017, Accessed on January 4 2018."},{"key":"10.3233\/JAD-180145_ref34","unstructured":"Hoffman-La Roche (2010) A study of gantenerumab in participants with prodromal Alzheimer\u2019s disease - ClinicalTrials.gov. Last updated November 7, 2017, Accessed on January 5 2018."},{"key":"10.3233\/JAD-180145_ref35","first-page":"91","article-title":"Methodological aspects of the phase II study AFF006 evaluating amyloid-beta -targeting vaccine AFFITOPE\u00ae AD02 in early Alzheimer\u2019s disease \u2013 prospective use of novel composite scales","volume":"2","author":"Hendrix","year":"2015","journal-title":"J Prev Alzheimers Dis"},{"key":"10.3233\/JAD-180145_ref40","unstructured":"Kile S , Sutter Health (2011) Study of intravenous immunoglobulin in amnestic mild cognitive impairment (MCI) - ClinicalTrials.gov. Last updated March 9, 2018, Accessed on March 31 2016."},{"key":"10.3233\/JAD-180145_ref41","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1111\/nan.12192","article-title":"Invited review: Drug development for tauopathies","volume":"41","author":"Gr\u00fcninger","year":"2015","journal-title":"Neuropathol Appl Neurobiol"},{"key":"10.3233\/JAD-180145_ref42","unstructured":"Boxer A , CBD Solutions, Tau Consortium, University of California San Francisco (2014) Safety study of TPI-287 to treat CBS and PSP (TPI-287-4RT) - ClinicalTrials.gov. Last updated December 7, 2016, Accessed on Januar 6 2018."},{"key":"10.3233\/JAD-180145_ref43","doi-asserted-by":"crossref","first-page":"323","DOI":"10.3233\/JAD-2008-13309","article-title":"Intranasal insulin administration dose-dependently modulates verbal memory and plasma amyloid-beta in memory-impaired older adults","volume":"13","author":"Reger","year":"2008","journal-title":"J Alzheimers Dis"},{"key":"10.3233\/JAD-180145_ref45","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/s13195-017-0308-0","article-title":"PKR involvement in Alzheimer\u2019s disease","volume":"9","author":"Hugon","year":"2017","journal-title":"Alzheimers Res Ther"},{"key":"10.3233\/JAD-180145_ref46","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.3390\/ijms15021719","article-title":"Use of genetically modified mesenchymal stem cells to treat neurodegenerative diseases","volume":"15","author":"Wyse","year":"2014","journal-title":"Int J Mol Sci"},{"key":"10.3233\/JAD-180145_ref47","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1007\/s12015-010-9190-x","article-title":"Mesenchymal stem cells stimulate endogenous neurogenesis in the subventricular zone of adult mice","volume":"7","author":"Kan","year":"2011","journal-title":"Stem Cell Rev"},{"key":"10.3233\/JAD-180145_ref48","doi-asserted-by":"crossref","first-page":"13594","DOI":"10.1073\/pnas.0901402106","article-title":"Neural stem cells improve cognition via BDNF in a transgenic model of Alzheimer disease","volume":"106","author":"Blurton-Jones","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.3233\/JAD-180145_ref49","doi-asserted-by":"crossref","first-page":"633","DOI":"10.3233\/JAD-131148","article-title":"IL12\/23 p40 inhibition ameliorates Alzheimer\u2019s disease-associated neuropathology and spatial memory in SAMP8 mice","volume":"38","author":"Tan","year":"2014","journal-title":"J Alzheimers Dis"},{"key":"10.3233\/JAD-180145_ref50","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1111\/ene.13583","article-title":"Increased expression of TREM2 in peripheral cells from mild cognitive impairment patients who progress into Alzheimer\u2019s disease","volume":"25","author":"Casati","year":"2018","journal-title":"Eur J Neurol"},{"key":"10.3233\/JAD-180145_ref52","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.neurobiolaging.2016.04.020","article-title":"Intracerebral adeno-associated virus gene delivery of apolipoprotein E2 markedly reduces brain amyloid pathology in Alzheimer\u2019s disease mouse models","volume":"44","author":"Zhao","year":"2016","journal-title":"Neurobiol Aging"},{"key":"10.3233\/JAD-180145_ref53","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.neuropharm.2017.06.026","article-title":"Cholesterol-metabolizing enzyme cytochrome P450 46A1 as a pharmacologic target for Alzheimer\u2019s disease","volume":"123","author":"Mast","year":"2017","journal-title":"Neuropharmacology"},{"key":"10.3233\/JAD-180145_ref54","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1080\/14656566.2017.1307340","article-title":"An update on the advancements in the treatment of agitation in Alzheimer\u2019s disease","volume":"18","author":"Porsteinsson","year":"2017","journal-title":"Expert Opin Pharmacother"},{"key":"10.3233\/JAD-180145_ref55","unstructured":"ACADIA Pharmaceuticals Inc (2017) A study of pimavanserin for the treatment of agitation and aggression in subjects with Alzheimer\u2019s disease - ClinicalTrials.gov. Last updated February 28, 2018, Accessed on March 29 2018."}],"container-title":["Journal of Alzheimer's Disease"],"original-title":[],"link":[{"URL":"https:\/\/content.iospress.com\/download?id=10.3233\/JAD-180145","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T10:07:44Z","timestamp":1777370864000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/full\/10.3233\/JAD-180145"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8,7]]},"references-count":38,"journal-issue":{"issue":"1"},"URL":"https:\/\/doi.org\/10.3233\/jad-180145","relation":{},"ISSN":["1387-2877","1875-8908"],"issn-type":[{"value":"1387-2877","type":"print"},{"value":"1875-8908","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,8,7]]}}}